Morgan Stanley reiterated coverage on Foghorn Therapeutics with a new price target

12/15/21 9:25:00 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Morgan Stanley reiterated coverage of Foghorn Therapeutics with a rating of Overweight and set a new price target of $26.00 from $23.00 previously

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$FHTX

Date	Price Target	Rating	Analyst
4/23/2025	$9.00	Mkt Outperform	Citizens JMP
1/30/2025	$10.00	Buy	B. Riley Securities
9/3/2024	$18.00	Buy	Jefferies
8/19/2024	$20.00	Outperform	Evercore ISI
3/28/2023	$10.00	Buy	BofA Securities
1/5/2023	$20.00	Outperform	BMO Capital Markets
12/15/2021	$23.00 → $26.00	Overweight	Morgan Stanley
11/22/2021	$25.00	Buy	HC Wainwright & Co.